多重耐药疟疾与大规模药物管理的影响
Multidrug-resistant malaria and the impact of mass drug administration.
作者信息
Zuber Janie Anne, Takala-Harrison Shannon
机构信息
Division of Malaria Research, Institute for Global Health, University of Maryland School of Medicine, Baltimore, MD, USA.
出版信息
Infect Drug Resist. 2018 Mar 1;11:299-306. doi: 10.2147/IDR.S123887. eCollection 2018.
Abstract
Based on the emergence and spread throughout the Greater Mekong Subregion (GMS) of multiple artemisinin-resistant lineages, the prevalence of multidrug resistance leading to high rates of artemisinin-based combination treatment failure in parts of the GMS, and the declining malaria burden in the region, the World Health Organization has recommended complete elimination of falciparum malaria from the GMS. Mass drug administration (MDA) is being piloted as one elimination intervention to be employed as part of this effort. However, concerns remain as to whether MDA might exacerbate the already prevalent problem of multidrug resistance in the region. In this review, we briefly discuss challenges of MDA, the use of MDA in the context of multidrug-resistant malaria, and the potential of different drug combinations and drug-based elimination strategies for mitigating the emergence and spread of resistance.
摘要
鉴于多种青蒿素抗性谱系在大湄公河次区域（GMS）出现并传播，导致该区域部分地区基于青蒿素的联合治疗失败率居高不下的多药耐药性普遍存在，以及该区域疟疾负担不断下降，世界卫生组织已建议在大湄公河次区域彻底消除恶性疟原虫疟疾。大规模药物管理（MDA）正在作为一项消除干预措施进行试点，作为这项工作的一部分加以采用。然而，对于MDA是否可能加剧该区域已经普遍存在的多药耐药性问题，人们仍然存在担忧。在这篇综述中，我们简要讨论了MDA面临的挑战、MDA在多药耐药性疟疾背景下的应用，以及不同药物组合和基于药物的消除策略在减轻耐药性出现和传播方面的潜力。
相似文献
1
Multidrug-resistant malaria and the impact of mass drug administration.多重耐药疟疾与大规模药物管理的影响
Infect Drug Resist. 2018 Mar 1;11:299-306. doi: 10.2147/IDR.S123887. eCollection 2018.
2
Safety and effectiveness of mass drug administration to accelerate elimination of artemisinin-resistant falciparum malaria: A pilot trial in four villages of Eastern Myanmar.群体服药加速清除青蒿素耐药恶性疟原虫疟疾的安全性和有效性：缅甸东部四个村庄的试点试验
Wellcome Open Res. 2017 Sep 6;2:81. doi: 10.12688/wellcomeopenres.12240.1. eCollection 2017.
3
Geographic expansion of artemisinin resistance.青蒿素耐药性的地理扩张。
J Travel Med. 2019 Jun 1;26(4). doi: 10.1093/jtm/taz030.
4
The promise, problems and pitfalls of mass drug administration for malaria elimination: a qualitative study with scientists and policymakers.大规模药物治疗根除疟疾的前景、问题与挑战：科学家和决策者的定性研究。
Int Health. 2019 May 1;11(3):166-176. doi: 10.1093/inthealth/ihy079.
5
Malaria trends and challenges in the Greater Mekong Subregion.大湄公河次区域的疟疾趋势与挑战
Southeast Asian J Trop Med Public Health. 2009 Jul;40(4):674-91.
6
Ivermectin susceptibility and sporontocidal effect in Greater Mekong Subregion Anopheles.大湄公河次区域按蚊对伊维菌素的敏感性及杀孢子体作用
Malar J. 2017 Jul 7;16(1):280. doi: 10.1186/s12936-017-1923-8.
7
Plasmodium falciparum Resistance to Artemisinin Derivatives and Piperaquine: A Major Challenge for Malaria Elimination in Cambodia.恶性疟原虫对青蒿素衍生物和哌喹的耐药性：柬埔寨疟疾消除面临的重大挑战。
Am J Trop Med Hyg. 2016 Dec 7;95(6):1228-1238. doi: 10.4269/ajtmh.16-0234. Epub 2016 Oct 17.
8
Mass drug administration can be a valuable addition to the malaria elimination toolbox.大规模药物治疗可以成为消除疟疾工具包的一个有价值的补充。
Malar J. 2019 Aug 22;18(1):281. doi: 10.1186/s12936-019-2906-8.
9
Combating multidrug-resistant Plasmodium falciparum malaria.对抗耐多药恶性疟原虫疟疾
FEBS J. 2017 Aug;284(16):2569-2578. doi: 10.1111/febs.14127. Epub 2017 Jun 30.
10
Resistance to Artemisinin Combination Therapies (ACTs): Do Not Forget the Partner Drug!对青蒿素联合疗法（ACTs）的耐药性：不要忘记辅助药物！
Trop Med Infect Dis. 2019 Feb 1;4(1):26. doi: 10.3390/tropicalmed4010026.
引用本文的文献
1
Rethinking malaria elimination: a perspective on challenges and solutions in Angola.重新思考疟疾消除：安哥拉面临的挑战与解决方案之展望
Malar J. 2025 Jul 2;24(1):214. doi: 10.1186/s12936-025-05398-3.
2
Mathematical models of Plasmodium vivax transmission: A scoping review.《疟原虫 vivax 传播的数学模型：范围综述》。
PLoS Comput Biol. 2024 Mar 14;20(3):e1011931. doi: 10.1371/journal.pcbi.1011931. eCollection 2024 Mar.
3
Assessment of antimalarial activity of crude extract of Chan-Ta-Lee-La and Pra-Sa-Chan-Dang formulations and their plant ingredients for new drug candidates of malaria treatment: In vitro and in vivo experiments.评估 Chan-Ta-Lee-La 和 Pra-Sa-Chan-Dang 制剂及其植物成分的抗疟活性，作为疟疾治疗新药候选物：体外和体内实验。
PLoS One. 2024 Jan 11;19(1):e0296756. doi: 10.1371/journal.pone.0296756. eCollection 2024.
4
Mapping resistance-associated anthelmintic interactions in the model nematode Caenorhabditis elegans.在模式线虫秀丽隐杆线虫中绘制与抗药性相关的驱虫剂相互作用图谱。
PLoS Negl Trop Dis. 2023 Oct 26;17(10):e0011705. doi: 10.1371/journal.pntd.0011705. eCollection 2023 Oct.
5
Antimalarial mass drug administration in large populations and the evolution of drug resistance.在大量人群中进行抗疟大规模药物给药与耐药性的演变。
PLOS Glob Public Health. 2023 Jul 26;3(7):e0002200. doi: 10.1371/journal.pgph.0002200. eCollection 2023.
6
Optimal Interruption of P. vivax Malaria Transmission Using Mass Drug Administration.采用大规模药物治疗中断间日疟传播的最适策略。
Bull Math Biol. 2023 Apr 19;85(6):43. doi: 10.1007/s11538-023-01153-4.
7
Ethical challenges in mass drug administration for reducing childhood mortality: a qualitative study.大规模药物治疗降低儿童死亡率的伦理挑战：定性研究。
Infect Dis Poverty. 2022 Sep 16;11(1):99. doi: 10.1186/s40249-022-01023-6.
8
Environmental impacts of mass drug administration programs: exposures, risks, and mitigation of antimicrobial resistance.大规模药物管理方案的环境影响：抗生素耐药性的暴露、风险和缓解。
Infect Dis Poverty. 2022 Jun 30;11(1):78. doi: 10.1186/s40249-022-01000-z.
9
Impact of Drug Pressure versus Limited Access to Drug in Malaria Control: The Dilemma.药物压力与疟疾控制中药物获取受限的影响：困境
Medicines (Basel). 2022 Jan 4;9(1):2. doi: 10.3390/medicines9010002.
10
Community knowledge, perceptions, and practices regarding malaria and its control in Jabi Tehnan district, Amhara Region, Northwest Ethiopia.埃塞俄比亚西北部阿姆哈拉地区贾比·特汉南地区社区对疟疾及其控制的知识、看法和做法。
Malar J. 2021 Dec 9;20(1):459. doi: 10.1186/s12936-021-03996-5.
本文引用的文献
1
Emergence of Plasmodium falciparum triple mutant in Cambodia.柬埔寨出现恶性疟原虫三重突变体。
Lancet Infect Dis. 2017 Dec;17(12):1233. doi: 10.1016/S1473-3099(17)30635-7.
2
Safety and effectiveness of mass drug administration to accelerate elimination of artemisinin-resistant falciparum malaria: A pilot trial in four villages of Eastern Myanmar.群体服药加速清除青蒿素耐药恶性疟原虫疟疾的安全性和有效性：缅甸东部四个村庄的试点试验
Wellcome Open Res. 2017 Sep 6;2:81. doi: 10.12688/wellcomeopenres.12240.1. eCollection 2017.
3
Population pharmacokinetics and electrocardiographic effects of dihydroartemisinin-piperaquine in healthy volunteers.双氢青蒿素-哌喹在健康志愿者中的群体药代动力学及心电图效应
Br J Clin Pharmacol. 2017 Dec;83(12):2752-2766. doi: 10.1111/bcp.13372. Epub 2017 Aug 16.
4
Ivermectin and malaria control.伊维菌素与疟疾防治
Malar J. 2017 Apr 24;16(1):172. doi: 10.1186/s12936-017-1825-9.
5
Treatment Failure of Dihydroartemisinin/Piperaquine for Plasmodium falciparum Malaria, Vietnam.越南双氢青蒿素/哌喹治疗恶性疟原虫疟疾的治疗失败情况
Emerg Infect Dis. 2017 Apr;23(4):715-717. doi: 10.3201/eid2304.161872.
6
The spread of artemisinin-resistant Plasmodium falciparum in the Greater Mekong subregion: a molecular epidemiology observational study.大湄公河次区域青蒿素耐药恶性疟原虫的传播：一项分子流行病学观察性研究。
Lancet Infect Dis. 2017 May;17(5):491-497. doi: 10.1016/S1473-3099(17)30048-8. Epub 2017 Feb 2.
7
Does antimalarial mass drug administration increase or decrease the risk of resistance?抗疟药物全民服药会增加还是降低抗药性风险？
Lancet Infect Dis. 2017 Jan;17(1):e15-e20. doi: 10.1016/S1473-3099(16)30269-9. Epub 2016 Nov 11.
8
A surrogate marker of piperaquine-resistant Plasmodium falciparum malaria: a phenotype-genotype association study.耐哌喹恶性疟原虫疟疾的替代标志物：一项表型-基因型关联研究。
Lancet Infect Dis. 2017 Feb;17(2):174-183. doi: 10.1016/S1473-3099(16)30415-7. Epub 2016 Nov 3.
9
Genetic markers associated with dihydroartemisinin-piperaquine failure in Plasmodium falciparum malaria in Cambodia: a genotype-phenotype association study.柬埔寨恶性疟原虫疟疾中与双氢青蒿素-哌喹治疗失败相关的遗传标记：一项基因型-表型关联研究。
Lancet Infect Dis. 2017 Feb;17(2):164-173. doi: 10.1016/S1473-3099(16)30409-1. Epub 2016 Nov 3.
10
Role of K13 Mutations in Artemisinin-Based Combination Therapy.K13突变在基于青蒿素的联合疗法中的作用。
Clin Infect Dis. 2016 Dec 15;63(12):1680-1681. doi: 10.1093/cid/ciw641. Epub 2016 Sep 22.
Zotero 插件